BCR-ABL-IN-8

• UNSPSC Description:

  BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor containing trimethoxy group[1].

• Target Antigen:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  cancer

• Assay Protocol:

  https://www.medchemexpress.com/bcr-abl-in-8.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC(OC)=C(C(OC)=C1)OC)NC2=CC=C(C)C(NC(C3=CN=C(NC4=CC=C(C)C(N)=C4)N=C3NC)=O)=C2

• Molecular Weight:

  571.63

• References & Citations:

  [1]Liang X, et al. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia. J Med Chem. 2016 Mar 10;59(5):1984-2004.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1808288-49-4